- Home
- IMTX vs OPK Comparison
IMTX vs OPK Comparison
Compare IMTX & OPK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMTX | OPK |
|---|---|---|
| Founded | N/A | 2006 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.0B |
| IPO Year | 2020 | 2011 |
Fundamental Metrics
Financial Performance| Metric | IMTX | OPK |
|---|---|---|
| Price | $9.00 | $1.36 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 3 |
| Target Price | ★ $19.00 | $1.60 |
| AVG Volume (30 Days) | 405.8K | ★ 4.4M |
| Earning Date | 05-13-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $606,879,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $25.91 | $4.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.05 | $0.98 |
| 52 Week High | $12.41 | $1.73 |
Technical Indicators
Market Signals| Indicator | IMTX | OPK |
|---|---|---|
| Relative Strength Index (RSI) | 42.53 | 51.45 |
| Support Level | $8.62 | $1.36 |
| Resistance Level | $10.67 | $1.41 |
| Average True Range (ATR) | 0.45 | 0.06 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 39.75 | 58.62 |
Price Performance
Historical ComparisonAbout IMTX Immatics N.V.
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
About OPK OPKO Health Inc.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.